Arterial remodeling and plasma volume expansion in caveolin-1-deficient mice.
Caveolin-1 (Cav-1) is essential for the morphology of membrane caveolae and exerts a negative influence on a number of signaling systems, including nitric oxide (NO) production and activity of the MAP kinase cascade. In the vascular system, ablation of caveolin-1 may thus be expected to cause arterial dilatation and increased vessel wall mass (remodeling). This was tested in Cav-1 knockout (KO) mice by a detailed morphometric and functional analysis of mesenteric resistance arteries, shown to lack caveolae. Quantitative morphometry revealed increased media thickness and media-to-lumen ratio in KO. Pressure-induced myogenic tone and flow-induced dilatation were decreased in KO arteries, but both were increased toward wild-type (WT) levels following NO synthase (NOS) inhibition. Isometric force recordings following NOS inhibition showed rightward shifts of passive and active length-force relationships in KO, and the force response to alpha(1)-adrenergic stimulation was increased. In contrast, media thickness and force response of the aorta were unaltered in KO vs. WT, whereas lumen diameter was increased. Mean arterial blood pressure during isoflurane anesthesia was not different in KO vs. WT, but greater fluctuation in blood pressure over time was noted. Following NOS inhibition, fluctuations disappeared and pressure increased twice as much in KO (38 +/- 6%) compared with WT (17 +/- 3%). Tracer-dilution experiments showed increased plasma volume in KO. We conclude that NO affects blood pressure more in Cav-1 KO than in WT mice and that restructuring of resistance vessels and an increased responsiveness to adrenergic stimulation compensate for a decreased tone in Cav-1 KO mice.
Albinsson
Sebastian
S
Department of Experimental Medical Science, Lund University, SE-221 84 Lund, Sweden.
Shakirova
Yulia
Y
Rippe
Anna
A
Baumgarten
Maria
M
Rosengren
Bert-Inge
BI
Rippe
Catarina
C
Hallmann
Rupert
R
Hellstrand
Per
P
Rippe
Bengt
B
Swärd
Karl
K
D000818:Animals; D001794:Blood Pressure / Q000502:physiology; D015153:Blotting, Western; D051242:Caveolin 1 / Q000172:deficiency* / Q000235:genetics; D004791:Enzyme Inhibitors / Q000494:pharmacology; D005455:Fluorescent Antibody Technique; D007537:Isometric Contraction / Q000187:drug effects; D007700:Kinetics; D008638:Mesenteric Arteries / Q000166:cytology / Q000187:drug effects / Q000502:physiology*; D051379:Mice; D008810:Mice, Inbred C57BL; D018345:Mice, Knockout; D046529:Microscopy, Electron, Transmission; D009119:Muscle Contraction / Q000187:drug effects / Q000502:physiology; D009129:Muscle Tonus / Q000502:physiology; D009213:Myography; D019331:NG-Nitroarginine Methyl Ester / Q000494:pharmacology; D052250:Nitric Oxide Synthase Type III / Q000037:antagonists & inhibitors; D009924:Organ Culture Techniques; D010952:Plasma Substitutes / Q000494:pharmacology*; D010953:Plasma Volume / Q000187:drug effects / Q000502:physiology*; D013936:Thymidine / Q000378:metabolism; D014664:Vasodilation / Q000502:physiology
D051242:Caveolin 1; D004791:Enzyme Inhibitors; D010952:Plasma Substitutes; D052250:Nitric Oxide Synthase Type III; D019331:NG-Nitroarginine Methyl Ester; D013936:Thymidine